Objective: To investigate whether serum Programmed death-1 (PD-1) levels elevate in patients with Adult-onset Still’s disease (AOSD) and determine their correlation with disease activity parameters.
Method: We enrolled 39 patients with AOSD 19 contr...
Objective: To investigate whether serum Programmed death-1 (PD-1) levels elevate in patients with Adult-onset Still’s disease (AOSD) and determine their correlation with disease activity parameters.
Method: We enrolled 39 patients with AOSD 19 controls. Serum samples from the patients with AOSD were assayed using an enzyme-linked immunosorbent assay (ELISA). A modified Pouchot score determined comprehensive AOSD activity.
Results: Serum sPD-1 levels were significantly higher in patients with AOSD (259.6±901.1, p < 0.01) than in control subjects (44.6±76.3, p < 0.01). Also, serum sPD-L2 levels were significantly higher in patients with AOSD (698.5±438.7, p < 0.01) than those in control subjects (168.0± 79.0, p < 0.01), whereas both levels of serum sPD-1 and serum sPD-L2 were not significantly different between inactive and active AOSD subgroups.
Serum sPD-1 in all subjects were positively correlated to serum sPD-L2(r = 0.681, p < 0.0001) and were negatively correlated to age (r = -0.336, p = 0.010) levels. Serum PD-L2 in all subjects were negatively correlated to Age (r = -0.224, p = 0.070).
Serum sPD-L2 levels in AOSD were positively correlated to age (p = 0.032), levels of serum sPD-1 (p< 0.001), LDH (p = 0.002), and Ferritin (p = 0.029). However, both serum levels of sPD-1 and serum sPD-L2 did not show any correlation with the modified Pouchot score.
When we stratified AOSD patients based on the 90th percentile of controls' levels, it showed an area under the curve (AUC) with a value of 72.6%. Using the AUC, we established cutoff values for clinical application. Thus, high levels of sPD-1 are mortality predictors in AOSD.